References:
1. De Waele L, Van Gaal P-J, Abramowicz D. Electrolytes disturbances after kidney transplantation. Acta Clinica Belgica 2019;74 (1):48-52
2. Jones J, Gruessner R, Gores P, Matas AJ. Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation. Transplantation 1993;56 (4):1013-15
3. Kaplan B, Wang Z, Abecassis MM, Fryer JP, Stuart FP, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation 1996;62 (8):1174-75
4. Alfonzo AV, Isles C, Geddes C, Deighan C. Potassium disorders—clinical spectrum and emergency management. Resuscitation 2006;70 (1):10-25
5. Davis T, Young B, Eisenberg M, Rea T, Copass M, Cobb L. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. Kidney international 2008;73 (8):933-39
6. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nature Reviews Nephrology 2014;10 (11):653
7. Pochineni V, Rondon-Berrios H. Electrolyte and acid-base disorders in the renal transplant recipient. Frontiers in medicine 2018;5 :261
8. Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E, Caravaca F. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease. Nefrología (English Edition) 2019;39 (5):513-22
9. Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study. Nephrology Dialysis Transplantation 2018;33 (9):1610-20
10. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med 2017;84 (12):934-42
11. Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrology Dialysis Transplantation 2004;19 (2):444-50
12. Menegussi J, Tatagiba LS, Vianna JGP, Seguro AC, Luchi WM. A physiology-based approach to a patient with hyperkalemic renal tubular acidosis. Brazilian Journal of Nephrology 2018;40 (4):410-17
13. Heering P, Kurschat C, Vo D, Klein‐Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down‐regulation of mineralocorticoid receptor expression 1. Clinical transplantation 2004;18 (2):186-92
14. Deppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombès M. Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology 2002;143 (5):1932-41
15. Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor Toxicity—What the FK? Advances in Chronic Kidney Disease 2020;27 (1):56-66
16. Choi MJ, Fernandez PC, Patnaik A, et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. New england journal of medicine 1993;328 (10):703-06
17. Shin J-I, Palta M, Djamali A, Kaufman DB, Astor BC. The association between renin-angiotensin system blockade and long-term outcomes in renal transplant recipients: The Wisconsin Allograft Recipient Database (WisARD). Transplantation 2016;100 (7):1541-49
18. Beccari MV, Meaney CJ. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Core Evidence 2017;12 :11
19. K/DOQI, National Kidney Foundation Clinical Practice Guidelines for nutrition in chronic renal failure. Am K Kidney Disease 2000; 35: S1-S140.
20. Nutrition for the post–renal transplant recipients. Transplantation proceedings; 2004. Elsevier.
21. Weaver CM. Potassium and health. Advances in Nutrition 2013;4 (3):368S-77S
22. Hoffman BF, Suckling E. Effect of several cations on transmembrane potentials of cardiac muscle. American Journal of Physiology-Legacy Content 1956;186 (2):317-24
23. Clase CM, Carrero J-J, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney international 2020;97 (1):42-61
24. Semple P, Both C. Calcium chloride; a reminder. Anaesthesia 1996;51 (1):93-93
25. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. The Journal of physiology 1883;4 (1):29
26. Winkler AW, Hoff HE, Smith PK. Factors affecting the toxicity of potassium. American Journal of Physiology-Legacy Content 1939;127 (3):430-36
27. Chamberlain M. Emergency treatment of hyperkalaemia. The Lancet 1964;283 (7331):464-67
28. Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database of Systematic Reviews 2015(10)
29. Truhlář A, Deakin CD, Soar J, et al. European resuscitation council guidelines for resuscitation 2015: section 4. Cardiac arrest in special circumstances. 2015
30. Calcium Gluconate [package insert]. Lake Zurich, IL: Fresenius Kabi; 2017.
31. Lane X, Montoliu J, Cases A, Campistol J, Revert L. Treatment of hyperkalaemia in renal failure: salbutamol v. insulin. Nephrology Dialysis Transplantation 1989;4 (3):228-32
32. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney international 1990;38 (5):869-72
33. Peacock WF, Rafique Z, Clark CL, et al. Real World Evidence for Treatment of Hyperkalemia in the Emergency Department (REVEAL–ED): A Multicenter, Prospective, Observational Study. The Journal of emergency medicine 2018;55 (6):741-50
34. LaRue HA, Peksa GD, Shah SC. A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2017;37 (12):1516-22
35. Pierce DA, Russell G, Pirkle Jr JL. Incidence of hypoglycemia in patients with low eGFR treated with insulin and dextrose for hyperkalemia. Annals of Pharmacotherapy 2015;49 (12):1322-26
36. Garcia J, Pintens M, Morris A, Takamoto P, Baumgartner L, Tasaka CL. Reduced versus conventional dose insulin for hyperkalemia treatment. Journal of Pharmacy Practice 2020;33 (3):262-66
37. Farina N, Anderson C. Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia. Therapeutic advances in drug safety 2018;9 (6):323-29
38. Moratinos J, Reverte M. Effects of catecholamines on plasma potassium: the role of alpha‐and beta‐adrenoceptors. Fundamental & clinical pharmacology 1993;7 (3‐4):143-53
39. Liou H-H, Chiang S-S, Wu S-C, et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure: comparative study. American journal of kidney diseases 1994;23 (2):266-71
40. McClure R, Prasad V, Brocklebank J. Treatment of hyperkalaemia using intravenous and nebulised salbutamol. Archives of disease in childhood 1994;70 (2):126-28
41. Effa E, Webster A. Pharmacological interventions for the management of acute hyperkalaemia in adults. Nephrology (Carlton, Vic.) 2017;22 (1):5
42. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Annals of internal medicine 1989;110 (6):426-29
43. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. Journal of the American Society of Nephrology 1995;6 (4):1134-42
44. Ngugi N, McLigeyo S, Kayima J. Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East African medical journal 1997;74 (8):503-09
45. Alfonzo A, Soar J, MacTier R, et al. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. UK Renal Association 2014
46. Burnell JM, Villamil MF, Uyeno BT, Scribner BH. THE EFFECT IN HUMANS OF EXTRACELLULAR p H CHANGE ON THE RELATIONSHIP BETWEEN SERUM POTASSIUM CONCENTRATION AND INTRACELLULAR POTASSIUM. The Journal of clinical investigation 1956;35 (9):935-39
47. SCHWARZ KC, COHEN BD, LUBASH GD, RUBIN AL. Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion. Circulation 1959;19 (2):215-20
48. Fraley DS, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney international 1977;12 (5):354-60
49. Mahoney BA, Smith WA, Lo D, Tsoi K, Tonelli M, Clase C. Emergency interventions for hyperkalaemia. Cochrane database of systematic reviews 2005(2)
50. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney international 1992;41 (2):369-74
51. Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of nephrology 2019;32 (4):499-516
52. Frohnert PP, Johnson WJ, Mueller GJ, Tauxe WN, McCall JT. Resin treatment of hyperkalemia. II. Clinical experience with a cation exchange resin (calcium cycle). Translational Research 1968;71 (5):840-46
53. Lillemoe K, Romolo J, Hamilton SR, Pennington L, Burdick JF, Williams G. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 1987;101 (3):267-72
54. Lepage L, Dufour A-C, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clinical Journal of the American Society of Nephrology 2015;10 (12):2136-42
55. Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. Journal of Ayub Medical College Abbottabad 2014;26 (4):455-8
56. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. The American journal of medicine 2013;126 (3):264. e9-64. e24
57. Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA internal medicine 2019;179 (8):1025-33
58. Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrology Dialysis Transplantation 2019
59. Parks M, Grady D. Sodium polystyrene sulfonate for hyperkalemia. JAMA Internal Medicine 2019;179 (8):1023-24
60. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? Journal of the American Society of Nephrology 2010;21 (5):733-35
61. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrology Dialysis Transplantation 2012;27 (12):4294-97
62. Veltassa [package insert]. Redwood city CR, LLC; 2015.
63. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I-Z. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. European heart journal 2011;32 (7):820-28
64. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. Jama 2015;314 (2):151-61
65. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC heart failure 2018;5 (3):257-66
66. Rafique Z, Almasary AN, Singer AJ. Contemporary treatment of hyperkalemia. Current Emergency and Hospital Medicine Reports 2016;4 (4):219-26
67. Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Patiromer: a clinical review. Current medical research and opinion 2016;32 (1):155-64
68. Bhattarai S, Pupillo S, Man Singh Dangol G, Sarac E. Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect. Case Reports in Nephrology 2019;2019
69. Wiederkehr MR, Mehta AN, Emmett M. Case report: Patiromer-induced hypercalcemia. Clinical nephrology. Case Studies 2019;7 :51
70. Lim MA, Sawinski D, Trofe-Clark J. Safety, effectiveness, and tolerability of patiromer in kidney transplant recipients. Transplantation 2019;103 (9):e281-e82
71. Rattanavich R, Malone AF, Alhamad T. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients. Transplant International 2019;32 (1):110-11
72. Clinical trials.gov. Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer.
73. Bounthavong M, Butler J, Dolan CM, et al. Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia. Pharmacoeconomics 2018;36 (12):1463-73
74. Astra Zeneca. Lokelma (sodium zirconium cyclosilicate) for oral suspension: Summary of Product Characteristics, 2018:https://www.ema.europa.eu/en/medicines/human/EPAR/lokelma.
75. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. New England Journal of Medicine 2015;372 (3):222-31
76. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. Jama 2014;312 (21):2223-33
77. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clinical Journal of the American Society of Nephrology 2019;14 (6):798-809
78. Winstead RJ, Demehin M, Yakubu I, et al. Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression. Clinical Transplantation 2020;34 (3):e13791
79. Jonathan Zalman SL, Amy Lugo, Leslie Ochs. Sodium zirconium cyclosilicate: new drug review and cost-minimization analysis. Poster presented at: ASHP Midyear; December,2019; Las Vegas, NV. 2019
80. Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis. Nephron 2002;92 (3):576-81
81. Kaisar MO, Wiggins KJ, Sturtevant JM, et al. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. American journal of kidney diseases 2006;47 (5):809-14
82. Marfo K, Glicklich D. Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia. Case reports in transplantation 2012;2012
83. Sivakumar V, Sriramnaveen P, Krishna C, et al. Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient. Saudi Journal of Kidney Diseases and Transplantation 2014;25 (1):149
84. Çağlayan FB, Koç Y, Baştürk T, et al. Aldosterone Resistance Due to Tacrolimus: A Case Report. Şişli Etfal Hastanesi Tip Bülteni 2018;52 (4):310-12
85. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. Bmj 2009;339
86. Taber DJ, Srinivas TM, Pilch NA, et al. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? American journal of nephrology 2013;38 (4):285-91
87. Hou S, McElroy PA, Nootens J, Beach M. Safety and efficacy of low-potassium dialysate. American Journal of Kidney Diseases 1989;13 (2):137-43
88. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney international 1980;17 (6):811-19
89. Dolson GM, Adrogue HJ. Low dialysate [K+] decreases efficiency of hemodialysis and increases urea rebound. Journal of the American Society of Nephrology 1998;9 (11):2124-28
90. Capdevila M, Martinez Ruiz I, Ferrer C, et al. The efficiency of potassium removal during bicarbonate hemodialysis. Hemodialysis International 2005;9 (3):296-302
91. Gutzwiller J, Schneditz D, Huber A, Schindler C, Garbani E, Zehnder C. Increasing blood flow increases kt/V (urea) and potassium removal but fails to improve phosphate removal. Clinical nephrology 2003;59 (2):130

Table 1. Food Rich in Potassium Content